These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 32927513)
1. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor]. Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513 [No Abstract] [Full Text] [Related]
2. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation]. Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512 [No Abstract] [Full Text] [Related]
3. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562 [No Abstract] [Full Text] [Related]
4. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation]. Qi C; Pan F; Li J; Li Y; Gao J; Shen L Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor. Huang W; Yuan W; Ren L; Liang H; Du X; Sun X; Fang Y; Gao X; Fu M; Sun Y; Shen K; Hou Y Pathol Res Pract; 2022 Nov; 239():154138. PubMed ID: 36183438 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China. Zhang P; Wang M; Li J; Gao X; Zhang B; Liang H; Zhou Y; Liao G; Feng F; Zhou Y; Yu J; Zhang J; Zhou Y; Ye Y; Chen J; Zhao Q; Shen K; Cao H; Tao K Adv Ther; 2022 Jun; 39(6):2920-2931. PubMed ID: 35462602 [TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926 [TBL] [Abstract][Full Text] [Related]
8. [Differences in clinicopathological features, gene mutations, and prognosis between primary gastric and intestinal gastrointestinal stromal tumors in 1061 patients]. Li JX; Sun L; Zhao S; Shao B; Guo YH; Chen S; Liang H; Sun Y Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):346-356. PubMed ID: 37072312 [No Abstract] [Full Text] [Related]
9. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666 [TBL] [Abstract][Full Text] [Related]
10. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review. Kanamori K; Yamagata Y; Honma Y; Date K; Wada T; Hayashi T; Otsuki S; Sekine S; Yoshikawa T; Katai H; Nishida T World J Surg Oncol; 2020 Jul; 18(1):183. PubMed ID: 32703220 [TBL] [Abstract][Full Text] [Related]
11. [Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor]. Yuan W; Huang W; Ren L; Liang HY; Dong SY; Du XY; Xu C; Fang Y; Shen KT; Hou YY Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):46-51. PubMed ID: 38178746 [No Abstract] [Full Text] [Related]
12. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172 [TBL] [Abstract][Full Text] [Related]
13. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations. Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580 [TBL] [Abstract][Full Text] [Related]
14. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704 [TBL] [Abstract][Full Text] [Related]
15. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M Front Immunol; 2020; 11():851. PubMed ID: 32670260 [TBL] [Abstract][Full Text] [Related]
16. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Smrke A; Gennatas S; Huang P; Jones RL Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495 [TBL] [Abstract][Full Text] [Related]
17. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108 [TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P; Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859 [TBL] [Abstract][Full Text] [Related]
19. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study. Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P; Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040 [TBL] [Abstract][Full Text] [Related]
20. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China]. Qiu H; Zhang P; Feng X; Chen T; Sun X; Yu J; Chen Z; Li Y; Tao K; Li G; Zhou Z Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1265-1270. PubMed ID: 27928797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]